Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants

Y. Sato, S. Iwata, Y. Kusumoto, H. Shiro, T. Oikawa, M. Osano

Research output: Contribution to journalArticle

Abstract

Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rate 'excellent' or 'good'. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.

Original languageEnglish
Pages (from-to)2582-2592
Number of pages11
JournalJapanese Journal of Antibiotics
Volume42
Issue number12
Publication statusPublished - 1989

Fingerprint

Cefmenoxime
Premature Infants
Pharmacokinetics
Newborn Infant
Eosinophilia
Bacterial Infections
Intravenous Infusions
Pharmaceutical Preparations
Intravenous Administration
Half-Life
Hemorrhage
Anti-Bacterial Agents
Injections
Clinical Studies
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Sato, Y., Iwata, S., Kusumoto, Y., Shiro, H., Oikawa, T., & Osano, M. (1989). Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants. Japanese Journal of Antibiotics, 42(12), 2582-2592.

Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants. / Sato, Y.; Iwata, S.; Kusumoto, Y.; Shiro, H.; Oikawa, T.; Osano, M.

In: Japanese Journal of Antibiotics, Vol. 42, No. 12, 1989, p. 2582-2592.

Research output: Contribution to journalArticle

Sato, Y, Iwata, S, Kusumoto, Y, Shiro, H, Oikawa, T & Osano, M 1989, 'Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants', Japanese Journal of Antibiotics, vol. 42, no. 12, pp. 2582-2592.
Sato Y, Iwata S, Kusumoto Y, Shiro H, Oikawa T, Osano M. Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants. Japanese Journal of Antibiotics. 1989;42(12):2582-2592.
Sato, Y. ; Iwata, S. ; Kusumoto, Y. ; Shiro, H. ; Oikawa, T. ; Osano, M. / Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants. In: Japanese Journal of Antibiotics. 1989 ; Vol. 42, No. 12. pp. 2582-2592.
@article{e440dd91997e4341ad73e436081f52ed,
title = "Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants",
abstract = "Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rate 'excellent' or 'good'. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.",
author = "Y. Sato and S. Iwata and Y. Kusumoto and H. Shiro and T. Oikawa and M. Osano",
year = "1989",
language = "English",
volume = "42",
pages = "2582--2592",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants

AU - Sato, Y.

AU - Iwata, S.

AU - Kusumoto, Y.

AU - Shiro, H.

AU - Oikawa, T.

AU - Osano, M.

PY - 1989

Y1 - 1989

N2 - Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rate 'excellent' or 'good'. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.

AB - Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rate 'excellent' or 'good'. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.

UR - http://www.scopus.com/inward/record.url?scp=0024806830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024806830&partnerID=8YFLogxK

M3 - Article

C2 - 2614915

AN - SCOPUS:0024806830

VL - 42

SP - 2582

EP - 2592

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 12

ER -